A Retrospective Study of Pregnancy and Fetal Outcomes in Mothers with Hepatitis C Viremia
A Retrospective Study of Pregnancy and Fetal Outcomes in Mothers with Hepatitis C Viremia

A Retrospective Study of Pregnancy and Fetal Outcomes in Mothers with Hepatitis C Viremia

Biomed Environ Sci. 2025 Jul 20;38(7):829-839. doi: 10.3967/bes2025.079.

ABSTRACT

OBJECTIVE: To investigate chronic hepatitis C virus (HCV) infection’s effect on gestational liver function, pregnancy and delivery complications, and neonatal development.

METHODS: A total of 157 HCV antibody-positive (anti-HCV[+]) and HCV RNA(+) patients (Group C) and 121 anti-HCV(+) and HCV RNA(-) patients (Group B) were included as study participants, while 142 anti-HCV(-) and HCV RNA(-) patients (Group A) were the control group. Data on biochemical indices during pregnancy, pregnancy complications, delivery-related information, and neonatal complications were also collected.

RESULTS: Elevated alanine aminotransferase (ALT) rates in Group C during early, middle, and late pregnancy were 59.87%, 43.95%, and 42.04%, respectively-significantly higher than Groups B (26.45%, 15.70%, 10.74%) and A (23.94%, 19.01%, 6.34%) ( P < 0.05). Median ALT levels in Group C were significantly higher than in Groups A and B at all pregnancy stages ( P < 0.05). No significant differences were found in neonatal malformation rates across groups ( P > 0.05). However, neonatal jaundice incidence was significantly greater in Group C (75.16%) compared to Groups A (42.25%) and B (57.02%) ( χ 2 = 33.552, P < 0.001). HCV RNA positivity during pregnancy was an independent risk factor for neonatal jaundice ( OR = 2.111, 95% CI 1.242-3.588, P = 0.006).

CONCLUSIONS: Chronic HCV infection can affect the liver function of pregnant women, but does not increase the pregnancy or delivery complication risks. HCV RNA(+) is an independent risk factor for neonatal jaundice.

PMID:40820249 | DOI:10.3967/bes2025.079